Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors
Status:
Completed
Trial end date:
2013-07-08
Target enrollment:
Participant gender:
Summary
This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This
study is designed to identify recommended doses and regimens in Japanese subjects for the
future development of GSK1120212.